C. Xu

3.0k citations

184 papers · 1.7k indexed · h-index 22

Impact in

Cancer Research top 5%
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
Oncology top 5%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies

Papers in ⓘ

Pulmonary and Respiratory Medicine 116
- Lung Cancer Treatments and Mutations 95
- Lung Cancer Diagnosis and Treatment 19
Oncology 86
- Lung Cancer Research Studies 32
- Colorectal Cancer Treatments and Studies 24
- Cancer Immunotherapy and Biomarkers 11

Co-authors: Wenxian Wang (71 shared papers)You‐cai Zhu (42 shared papers)Zhengbo Song (29 shared papers)Huafei Chen (20 shared papers)Wu Zhuang (33 shared papers)Kaiqi Du (23 shared papers)Meiyu Fang (23 shared papers)Yong Song (34 shared papers)
Journals: Journal of Thoracic Oncology (26 papers)Journal of Clinical Oncology (14 papers)Lung Cancer (7 papers)Cellular and Molecular Biology (6 papers)OncoTargets and Therapy (5 papers)
Partner nations: China United States Taiwan

In The Last Decade

C. Xu

164 papers receiving 1.7k citations

Peers

Countries citing papers authored by C. Xu

Since Specialization

Citations

This map shows the geographic impact of C. Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Xu more than expected).

Fields of papers citing papers by C. Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Xu. The network helps show where C. Xu may publish in the future.

Co-authors

The 25 scholars most cited alongside C. Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C. Xu Line = papers co-authored together C. Xu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 184 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation Experimental and Therapeutic Medicine ·Bo Zhang, C. Xu, Yun Shao, H. Wang, YONG-FANG WU, YE-YING SONG, XIAO-BING LI, Zhe Zhang, W.P. Wang, Liqiong Li, CONG-LI CAI	2015	83
2	TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma EBioMedicine ·Wenjing Xiao, Nan Du, Taoyuan Huang, Jinan Guo, Xingkui Mo, Tao Yuan, Yong Chen, Ting Ye, C. Xu, Wenxian Wang, Guoqiang Wang, Shangli Cai, Jing Chen	2018	53
3	Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study Lung Cancer ·Wenxian Wang, C. Xu, Huafei Chen, Jinhao Jia, Liping Wang, Huijing Feng, Hong Wang, Zhengbo Song, Nong Yang, Yongchang Zhang	2021	50
4	Robotic surgical systems in maxillofacial surgery: a review International Journal of Oral Science ·Hanghang Liu, Longjiang Li, Bin Shi, C. Xu, En Luo	2017	50
5	Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer Lung Cancer ·Zhengbo Song, Guoping Cheng, C. Xu, Wenxian Wang, Yang Shao, Yiping Zhang	2018	38
6	The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study Cancer Immunology Immunotherapy ·Wenxian Wang, Xiaodong Gu, Liping Wang, Xingxiang Pu, Huijing Feng, C. Xu, Guangyuan Lou, Lan Shao, Yibing Xu, Qian Wang, Siyuan Wang, Wenbin Gao, Yiping Zhang, Zhengbo Song	2021	35
7	The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients European Journal of Nuclear Medicine and Molecular Imaging ·Zhengbo Song, Tianchi Liu, Lei Shi, Zongyang Yu, Qing Shen, Mengdi Xu, Zhangzhou Huang, Zhijian Cai, Wenxian Wang, C. Xu, Jingjing Sun, Ming Chen	2020	33
8	TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib Journal of Thoracic Disease ·Wenxian Wang, C. Xu, Yanping Chen, Wei Liu, Lihua Zhong, Fangfang Chen, Wu Zhuang, Yunjian Huang, Zhangzhou Huang, Rongrong Chen, Yanfang Guan, Xin Yi, Tang-Feng Lv, Weifeng Zhu, Jianping Lu, Xiaojiang Wang, Yi Shi, Xiandong Lin, Gang Chen, Yong Song	2018	32
9	Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial Clinical Cancer Research ·Zhengbo Song, Dongqing Lv, Shiqing Chen, Jianjin Huang, Yuping Li, Shenpeng Ying, Xiaoyu Wu, Feng Hua, Wenxian Wang, C. Xu, Ting Bei, Chan Gao, Zhijian Sun, Yiping Zhang, Shun Lü	2021	31
10	MicroRNA-221 promotes cisplatin resistance in osteosarcoma cells by targeting PPP2R2A Bioscience Reports ·Wenchao Yu, Hui-hao Chen, QU Yan-yan, C. Xu, Yang Chen, Yan Liu	2019	31
11	Detoxification of Aflatoxin B1 by a Potential Probiotic Bacillus amyloliquefaciens WF2020 Frontiers in Microbiology ·Guojun Chen, Qian’an Fang, Zhenlin Liao, C. Xu, Zhibo Liang, Tong Liu, Qingping Zhong, Li Wang, Xiang Fang, Jie Wang	2022	30
12	Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study Journal of Translational Medicine ·Wenxian Wang, Hong Wang, Pei‐Hua Lu, Zongyang Yu, C. Xu, Wu Zhuang, Zhengbo Song	2019	28
13	OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway Journal of Korean Medical Science ·Hua Li, Qian Miao, C. Xu, Jian-hui Huang, Y. Zhou, Meijuan Wu	2016	27
14	Patients harboring <em>ALK </em>rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report OncoTargets and Therapy ·You‐cai Zhu, Xing‐hui Liao, Wenxian Wang, C. Xu, Wu Zhuang, Lihua Zhong, Kaiqi Du, Yanping Chen, Gang Chen, Meiyu Fang	2017	27
15	Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study Clinical Lung Cancer ·Tianle Shen, Xingxiang Pu, Liping Wang, Zongyang Yu, Jinluan Li, Yinbin Zhang, Xianbin Liang, Huafei Chen, C. Xu, Zhengbo Song, Wenxian Wang	2020	27
16	MiR-513c suppresses neuroblastoma cell migration, invasion, and proliferation through direct targeting glutaminase (GLS) Cancer Biomarkers ·Hongliang Xia, Yao Lv, C. Xu, Mingcui Fu, Ting Zhang, Xiangming Yan, Shu Dai, Qianwei Xiong, Yun Zhou, Jianwen Wang, Xu Cao	2017	27
17	A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations Translational Oncology ·Lei Lei, Wenxian Wang, Zongyang Yu, Xianbin Liang, Weiwei Pan, Huafei Chen, Liping Wang, Yong Fang, Min Wang, C. Xu, Meiyu Fang	2019	25
18	Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs Translational Oncology ·C. Xu, Lei Lei, Wenxian Wang, Lin Li, You‐cai Zhu, Hong Wang, Liyun Miao, Liping Wang, Wu Zhuang, Meiyu Fang, Tangfeng Lv, Yong Song	2020	25
19	Clinicopathological observation of primary lung enteric adenocarcinoma and its response to chemotherapy: A case report and review of the literature Experimental and Therapeutic Medicine ·Lin Li, C. Xu, Bo Zhang, RONG-RUI LIU, Fei-Jiao Ge, Chuanhua Zhao, Ru Jia, Quan-Hong Qin, Jelena Stojšić, Yan Wang, JIAN-MING XU	2015	23
20	Ginsenoside compound K inhibits growth of lung cancer cells via HIF-1Î±-mediated glucose metabolism Cellular and Molecular Biology ·Huafei Chen, Lixin Wu, Xiaofeng Li, You‐cai Zhu, Wenxian Wang, C. Xu, Zhangzhou Huang, Kai-qi Du	2019	23

About C. Xu

C. Xu is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Surgery, having authored 184 papers that have together received 1.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (95 papers), Lung Cancer Research Studies (32 papers), Cancer Genomics and Diagnostics (26 papers), Colorectal Cancer Treatments and Studies (24 papers), Lung Cancer Diagnosis and Treatment (19 papers), RNA modifications and cancer (17 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (11 papers). The work is most often cited by research in Cancer Research (471 citations), Oncology (795 citations), Pulmonary and Respiratory Medicine (945 citations), Molecular Biology (589 citations) and Pathology and Forensic Medicine (154 citations). C. Xu has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Wenxian Wang, You‐cai Zhu, Zhengbo Song, Huafei Chen, Wu Zhuang, Kaiqi Du, Meiyu Fang, Yong Song, Tangfeng Lv and Lixin Wu. Their work appears in journals such as Journal of Thoracic Oncology, Journal of Clinical Oncology, Lung Cancer, Cellular and Molecular Biology and OncoTargets and Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact